Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genentech, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Signed Informed Consent Form
Histologically or cytologically confirmed NSCLC
Advanced NSCLC or recurrent disease
INR no greater than 1.3 and aPTT no greater than upper limits of normal (ULN) within 28 days prior to enrollment for subjects not on low molecular weight heparin or fondaparinux. Subjects on low molecular weight heparin or fondaparinux are not required to meet INR or aPTT limits. Chronic full-dose anticoagulation with warfarin is not permitted.
18 years of age or older
For women of childbearing potential and sexually active men, use of an accepted and effective method of contraception (hormonal or barrier methods, abstinence) prior to enrollment and for the duration of the study
You may not be if
Prior systemic chemotherapy in the metastatic setting
Treatment with an investigational or marketed agent that acts by either EGFR inhibition or anti-angiogenesis mechanisms
Pregnancy or lactation
Any other medical condition, including mental illness or substance abuse, deemed by the clinician to be likely to interfere with a subject's ability to provide informed consent, cooperate, and participate in the study, or to interfere with the interpretation of the results
Active infection or a fever within 3 days of enrollment
Active malignancy other than lung cancer
Radiation therapy to sites other than whole brain within 14 days prior to enrollment
History of gross hemoptysis within 3 months prior to enrollment
Known hypersensitivity to any of the components of cytotoxic chemotherapy combinations, bevacizumab, or tyrosine kinase inhibitors
Inadequately controlled hypertension
Unstable angina or New York Heart Association Grade II or greater CHF
Abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to enrollment
History of myocardial infarction within 6 months prior to enrollment
History of stroke within 6 months prior to enrollment
Symptomatic peripheral vascular disease within 6 months prior to enrollment
Evidence of bleeding diathesis or coagulopathy
Serious, non-healing wound, ulcer, or bone fracture
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to enrollment; anticipation of need for major surgical procedure during the course of the study
Current, recent, or planned participation in an experimental drug study other than this Genentech-sponsored bevacizumab/erlotinib study
Progressive neurologic symptoms in subjects with a history of brain metastases
History of significant vascular disease (e.g., aortic aneurysm)
Clareo Health | A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS)
